Filament Health, a wholly owned subsidiary of Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) (OTCQB: TRUFF), has signed an agreement with ARQ National Psychotrauma Centre in the Netherlands to supply its botanical psilocybin drug candidate, PEX010, for a pilot clinical study focused on military veterans with post-traumatic stress disorder.

The study, titled "Psilocybin-Assisted Psychotherapy for Posttraumatic Stress Disorder in Military Veterans: A Pilot Feasibility Study," will use PEX010 as the investigational drug product. ARQ National Psychotrauma Centre is based in Diemen, the Netherlands, and specializes in the diagnosis and treatment of complex psychotrauma conditions, including those affecting military veterans.

According to the company's press release, PEX010 has been supplied to more than 80 academic and clinical studies worldwide. Red Light Holland completed its acquisition of Filament Health prior to this agreement, expanding its pharmaceutical manufacturing and clinical research operations.

"Being able to support this study with a reliable supply of PEX010 is something we are very proud of," said Todd Shapiro, Chief Executive Officer and Director of Red Light Holland.

Red Light Holland is an Ontario-based company operating within the legal psychedelic sector, with commercial activities in Europe and North America, including psilocybin truffle sales in the Netherlands.